Latest Safety News

Amplia Therapeutics reports encouraging interim results from its ACCENT trial, with its drug narmafotinib improving progression-free survival and response rates in advanced pancreatic cancer.

Charter Hall Long WALE REIT reports a $118.3 million statutory profit for FY25, reversing last year's heavy loss, while maintaining stable distributions and actively managing debt facilities.

Horseshoe Metals advances its Horseshoe Lights copper-gold project with mining approval secured, site mobilization underway, and new drilling planned to expand resources.

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

Element 25 Limited is advancing its Butcherbird Manganese Mine expansion in Western Australia alongside a new US-based refinery, backed by strong financing and partnerships with major automakers for EV battery-grade manganese supply.

Activeport Group Ltd has announced a fully underwritten rights issue to raise up to $2.5 million, offering shareholders discounted shares and free options to accelerate growth initiatives.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.

Beach Energy has reported a robust FY25 performance marked by significant production growth, record free cash flow, and strategic progress on key projects like the Waitsia Gas Plant and Moomba CCS. The company’s disciplined cost management and gas marketing strategy underpin a confident outlook for FY26.

Beach Energy reported robust FY25 results marked by significant cost reductions, increased production, and record dividends, while advancing key projects like the Waitsia Gas Plant and Moomba CCS.